Department of Clinical Chemistry and Haematology, Rijnstate Hospital, Arnhem, The Netherlands.
Department of Otorhinolaryngology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Clin Exp Allergy. 2019 Mar;49(3):350-356. doi: 10.1111/cea.13307. Epub 2018 Dec 18.
The gold standard for the diagnosis of cow's milk allergy is the Double-Blind Placebo-Controlled Food Challenge (DBPCFC) test. However, disadvantages of the DBPCFC are the potential risk of anaphylactic reactions, the time-consuming procedure and high costs.
The aim of this study was to determine the reliability of the Basophil Activation Test (BAT) both for the initial diagnosis of cow's milk allergy in children and for the determination of tolerance in children with cow's milk allergy.
Ninety-seven BATs and cow's milk-specific IgE (sIgE) tests were performed in 86 infants/young children, suspected of (persistent) cow's milk allergy, who were qualified for an in-hospital DBPCFC. The BAT was performed with cow's milk extract and the purified major allergens casein, α-lactalbumin, β-lactoglubulin. Basophil activation was determined by CD63 upregulation measured by flow cytometry. The BAT results were compared to the DBPCFC outcomes.
Based on unequivocal DBPCFC and BAT result combinations (80%), the BAT had a sensitivity and specificity of 100% (CI: 86%-100% and 68%-100%, respectively) in IgE-sensitized children (41% of the tested children). All non-IgE-sensitized children (59%) had a negative DBPCFC and BAT, except for five patients. These latter showed delayed and relatively mild symptoms in the DBPCFC with a negative BAT, supporting a non-IgE-mediated allergy in these children.
The BAT seems reliable and cost-effective to diagnose patients with an IgE-mediated cow's milk allergy. In IgE-sensitized patients, a BAT might replace a DBPCFC. For non-IgE-sensitized patients presenting with mild symptoms, we propose to consider a (double-blind) extended (time) challenge test at home.
牛奶过敏的诊断金标准是双盲安慰剂对照食物激发试验(DBPCFC)。然而,DBPCFC 存在潜在的过敏反应风险、耗时且费用高的缺点。
本研究旨在确定嗜碱性粒细胞活化试验(BAT)在儿童牛奶过敏的初始诊断和牛奶过敏儿童的耐受性测定中的可靠性。
对 86 名疑似(持续性)牛奶过敏且有条件进行住院 DBPCFC 的婴儿/幼儿进行了 97 次 BAT 和牛奶特异性 IgE(sIgE)检测。使用牛奶提取物和纯化的主要过敏原酪蛋白、α-乳白蛋白、β-乳球蛋白进行 BAT。通过流式细胞术测定 CD63 上调来确定嗜碱性粒细胞的活化。将 BAT 结果与 DBPCFC 结果进行比较。
根据明确的 DBPCFC 和 BAT 结果组合(80%),在 IgE 致敏儿童中(占检测儿童的 41%),BAT 的敏感性和特异性分别为 100%(CI:86%-100%和 68%-100%)。所有非 IgE 致敏儿童(59%)的 DBPCFC 和 BAT 均为阴性,除了 5 名患者。这些患者在 DBPCFC 中表现出延迟和相对较轻的症状,而 BAT 为阴性,提示这些儿童存在非 IgE 介导的过敏反应。
BAT 似乎可用于可靠且具有成本效益地诊断 IgE 介导的牛奶过敏患者。在 IgE 致敏患者中,BAT 可能替代 DBPCFC。对于出现轻度症状的非 IgE 致敏患者,我们建议在家中进行(双盲)扩展(时间)激发试验。